Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen

January 26, 2016
As governments worldwide get more and more rigorous about drug spending, pharma giants have started contemplating the option of excluding Japan from their global development amid uncertainties surrounding proposed annual drug price revisions and the weaker yen. Such move is...read more